A first-in-class nanoparticle injection sneaks antibodies into pancreatic cancer cells to clear mutant KRAS, shrinking tumors ...
Researchers at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) have discovered a previously unknown ...
KRAS is a commonly mutated oncogene and therapeutic targeting of KRAS mutants is critical for the development of new cancer therapies. KRAS mutations are frequently observed in aggressive cancers, ...
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor ...
A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical ...
A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR ...
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple ...
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater ...
KRAS‑mutant pancreatic cancer relies on caspase‑8 to evade necroptosis, according to a new study in preclinical models.
A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive ...
KRAS is a small GTPase oncogene that, when mutated, drives aberrant signalling through the RAS–RAF–MEK–ERK cascade, promoting tumour cell proliferation, survival and metastatic dissemination. Roughly ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results